Literature DB >> 29944461

Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.

Dongyoul Lee1, Mengshi Li1, Bryan Bednarz2, Michael K Schultz1,3,4,5,6,7.   

Abstract

The use of targeted radionuclide therapy for cancer is on the rise. While beta-particle-emitting radionuclides have been extensively explored for targeted radionuclide therapy, alpha-particle-emitting radionuclides are emerging as effective alternatives. In this context, fundamental understanding of the interactions and dosimetry of these emitted particles with cells in the tumor microenvironment is critical to ascertaining the potential of alpha-particle-emitting radionuclides. One important parameter that can be used to assess these metrics is the S-value. In this study, we characterized several alpha-particle-emitting radionuclides (and their associated radionuclide progeny) regarding S-values in the cellular and tumor-metastasis environments. The Particle and Heavy Ion Transport code System (PHITS) was used to obtain S-values via Monte Carlo simulation for cell and tumor metastasis resulting from interactions with the alpha-particle-emitting radionuclides, lead-212 (212Pb), actinium-225 (225Ac) and bismuth-213 (213Bi); these values were compared to the beta-particle-emitting radionuclides yttrium-90 (90Y) and lutetium-177 (177Lu) and an Auger-electron-emitting radionuclide indium-111 (111In). The effect of cellular internalization on S-value was explored at increasing degree of internalization for each radionuclide. This aspect of S-value determination was further explored in a cell line-specific fashion for six different cancer cell lines based on the cell dimensions obtained by confocal microscopy. S-values from PHITS were in good agreement with MIRDcell S-values (cellular S-values) and the values found by Hindié et al. (tumor S-values). In the cellular model, 212Pb and 213Bi decay series produced S-values that were 50- to 120-fold higher than 177Lu, while 225Ac decay series analysis suggested S-values that were 240- to 520-fold higher than 177Lu. S-values arising with 100% cellular internalization were two- to sixfold higher for the nucleus when compared to 0% internalization. The tumor dosimetry model defines the relative merit of radionuclides and suggests alpha particles may be effective for large tumors as well as small tumor metastases. These results from PHITS modeling substantiate emerging evidence that alpha-particle-emitting radionuclides may be an effective alternative to beta-particle-emitting radionuclides for targeted radionuclide therapy due to preferred dose-deposition profiles in the cellular and tumor metastasis context. These results further suggest that internalization of alpha-particle-emitting radionuclides via radiolabeled ligands may increase the relative biological effectiveness of radiotherapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29944461      PMCID: PMC6512332          DOI: 10.1667/RR15081.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  56 in total

1.  Track structures and dose distributions from decays of (131)I and (125)I in and around water spheres simulating micrometastases of differentiated thyroid cancer.

Authors:  W B Li; W Friedland; E Pomplun; P Jacob; H G Paretzke; M Lassmann; C Reiners
Journal:  Radiat Res       Date:  2001-10       Impact factor: 2.841

2.  Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.

Authors:  H R Balon; S J Goldsmith; B A Siegel; E B Silberstein; E P Krenning; O Lang; K J Donohoe
Journal:  J Nucl Med       Date:  2001-07       Impact factor: 10.057

Review 3.  Antibody-targeted radiation cancer therapy.

Authors:  Diane E Milenic; Erik D Brady; Martin W Brechbiel
Journal:  Nat Rev Drug Discov       Date:  2004-06       Impact factor: 84.694

4.  Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?

Authors:  Daniel Storch; Martin Béhé; Martin A Walter; Jianhua Chen; Pia Powell; Renata Mikolajczak; Helmut R Mäcke
Journal:  J Nucl Med       Date:  2005-09       Impact factor: 10.057

5.  Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres.

Authors:  M Bardiès; J F Chatal
Journal:  Phys Med Biol       Date:  1994-06       Impact factor: 3.609

6.  Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

Authors:  Marion de Jong; Wout A P Breeman; Roelf Valkema; Bert F Bernard; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

7.  High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor.

Authors:  M O Meyers; L B Anthony; K E McCarthy; G Drouant; T J Maloney; G D Espanan; E A Woltering
Journal:  South Med J       Date:  2000-08       Impact factor: 0.954

Review 8.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

Authors:  Marion De Jong; Roelf Valkema; Francois Jamar; Larry K Kvols; Dik J Kwekkeboom; Wout A P Breeman; Willem H Bakker; Chuck Smith; Stanislas Pauwels; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

9.  Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.

Authors:  Lowell B Anthony; Eugene A Woltering; Gregory D Espenan; Michele D Cronin; Tom J Maloney; Kevin E McCarthy
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

Review 10.  Peptide receptors as molecular targets for cancer diagnosis and therapy.

Authors:  Jean Claude Reubi
Journal:  Endocr Rev       Date:  2003-08       Impact factor: 19.871

View more
  2 in total

Review 1.  Medical application of particle and heavy ion transport code system PHITS.

Authors:  Takuya Furuta; Tatsuhiko Sato
Journal:  Radiol Phys Technol       Date:  2021-06-30

2.  Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand 212Pb-NG001.

Authors:  Vilde Yuli Stenberg; Anna Julie Kjøl Tornes; Hogne Røed Nilsen; Mona-Elisabeth Revheim; Øyvind Sverre Bruland; Roy Hartvig Larsen; Asta Juzeniene
Journal:  Cancers (Basel)       Date:  2022-06-03       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.